Community Research and Development Information Service - CORDIS

H2020

LUCY Report Summary

Project ID: 697269

Periodic Reporting for period 1 - LUCY (Early detector of comorbid depression)

Reporting period: 2015-10-01 to 2016-01-31

Summary of the context and overall objectives of the project

Depression is recognized as an increasing emergency at world level; it is among the leading causes of disability in persons 15 years and older.
Quality-adjusted life expectancy (QALE) loss among western country adults due to depression is calculated on 28.9-year at age 18. It exceeds estimates reported elsewhere for stroke (12.4-year loss), heart disease (10.3-year loss), diabetes mellitus (11.1-year loss), hypertension (6.3-year loss), asthma (7.0-year loss), smoking (11.0-year loss), and physical inactivity (8.0-year loss).
Prevalence and impact of depression are particularly harmful when they appear as comorbidity to other diseases; individuals affected by chronic diseases may be subject to a higher risk of comorbid depressive disorders than the general population but in particular are much severely impacted if a comorbid depression condition takes place, drastically worsening course and increasing mortality.
Depression comorbid with one or more pathological conditions and associated drug therapies significantly amplifies the loss of QALE (Quality-adjusted life expectancy), worsening the course of chronic diseases and lowering the adhesion to treatments
People at risk do not usually receive appropriate universal screening over time aimed at early diagnosis; conventional clinical practice based on extensive use of human resources cannot realistically cope with such a challenge.
Lucy is a cross-platform cloud environment continuously collecting biomarkers belonging to psychic and relational life of the person, like anxiety, depression, pain, disability, relational impairment, an advanced relational system, characterized by very low cost for the patient, elaborates information and translates it into objective and communicable data available to physicians, providing continuous, updated patient monitoring, through data-mining and smart on the go doctor interface.
The main objective of the development project will be to implement system scale-up and perform extensive multi-centric clinical validation.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

During Phase 1, work has been focused on developing deeper understanding of market and users’ demands, establishing a sound framework for future clinical validation activities, including the definition of a worldwide network of clinical validation centers, and developing a business plan for successful market introduction; the following activities have been performed:

- Development of an original comprehensive epidemiological study based on world literature, aimed at identifying diseases more impacted by comorbid depression, to be selected as target disease
for the use of LUCY

- Quantification of the number of patients in Europe and USA eventually affected by depression comorbid to more severely impacted chronic diseases

- Identification and critical analysis of standard clinical practice in chronic diseases management; identification of pain points and constraints

- Development of LUCY implementation paradigm in clinical contests, with the definition of the competitive advantage of LUCY with respect to standard operative practice and potential competitors

- Analysis of public and private health structures for target countries, with specific reference to public and private hospitals

- Identification of standardization and certification procedures to be followed to comply with healthcare regulations and guidelines in view of FDA certification

- Definition of LUCY target product development during Phase II and beyond, incorporating outcomes from market analysis and end-users’ involvement, including scale-up infrastructure
requirements and integration of added-value services

-Analysis of possible revenue models, selection of appropriate revenue model, definition of market segmentation, development of product line-up and pricing strategy

- Definition of a financial plan, forecasting revenues sales volumes and revenues for LUCY market introduction and commercialization

- IPRs recognition, patentability assessment, freedom of exploitation; trademark anteriority search, deposit of commercial trademark

Main results achieved so far:

- A clear picture has been produced about the impact depression generates in individuals affected by 7 major chronic disease affecting overall 170 M people in Europe and 140 M people in USA
By way of example, people with stroke affected by depression suffer from a risk of death which is reported to be between 30% and 50% higher; similar values are reported for course, involving
relapses, complications, hospital readmissions and further therapies

- An analysis of conventional medical practice allowed to highlight significant shortcomings, constraints and pain points, detecting general awareness by healthcare professionals that new models
have to be implemented and enabled.

- A complete set of technical product development specifications have been produced, complying with the implementation scenario generated by the analysis of conventional practice and users’
interviews.

- A long term product development roadmap, including the definition of the Minimum Viable Product and incremental development stages has been produced, including the identification of added
value services increasing LUCY

- The Group of worldwide clinical Validation Centres has been identified, including 10 major renowned partners from 8 countries in Europe, USA and South America, targeting a randomized screening
involving nearly 1,500 patients, a preliminary version of the clinical validation protocol has been agreed

- Economic projections developed confirm LUCY remarkable market potential

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

The broad range of analyses performed confirmed the innovative value of LUCY and the socio-economical relevance of the problem addressed, strengthening our original vision and commitment.
LUCY paradigm is expected to enable a novel, powerful relational model between patient and doctor, empowering patient, improving adhesion, safeguarding his/her health and making quality care easier for the doctor.
Pervasive screening is enabled by a comprehensive platform targeted to early detection of mood disorders and depression; the new operational model is expected to provide outstanding benefits on the course of diseases, for the advantage of both patients, physicians and society, reducing the economic burden due to the increasing prevalence of depression in population.

Related information

Record Number: 186434 / Last updated on: 2016-07-12